Mercator MedSystems

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Mercator MedSystems sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 3 currently recruiting 3 completed upper quartile by trial count

Mercator MedSystems: 7 sponsored US clinical trials, 3 recruiting.

Mercator MedSystems sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Iliofemoral; Thrombosis, with 2 trials.

Upper-quartile sponsor footprint

Mercator MedSystems sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 3

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

NCT04433572
RECRUITING Phase 2

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

NCT04858776
RECRUITING Phase 2

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

NCT04862468
TERMINATED Phase 2

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

NCT03942601
COMPLETED

DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes

NCT02469532
COMPLETED NA

Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients

NCT02066103
COMPLETED Phase 4

Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease

NCT01983449

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 1
Phase 4 1

Therapeutic Areas

Iliofemoral; Thrombosis 2
Thrombosis, Deep Vein 1
Critical Limb Ischemia 1
Peripheral Artery Disease 1

What is open in the Mercator MedSystems pipeline

3 recruiting of 7 indexed (43% open); 3 completed (43%).

Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).

Top condition: Iliofemoral; Thrombosis (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Mercator MedSystems: open-pipeline peers nationwide

Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.

Mercator MedSystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 6.97.07.077.07.07.1 0%10%20%30%40%50% Total trials Recruiting share Mercator MedSystems3M4Life Research89bioAbbott Diagnostics DivisionAlphatec SpineClarity PharmaceuticalsColorado Center for Reproductive MedicineDavid Moss
Mercator MedSystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mercator MedSystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 43% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mercator MedSystems page

7 registered trials is a research-attention snapshot, not an endorsement of Mercator MedSystems or any single study.

  • 3 of Mercator MedSystems's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Iliofemoral; Thrombosis is the condition Mercator MedSystems studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Iliofemoral; Thrombosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Mercator MedSystems pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.